A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors | Zendy

AI Assistant Blog Pricing

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.